These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33397677)

  • 1. Stereotypic neutralizing V
    Kim SI; Noh J; Kim S; Choi Y; Yoo DK; Lee Y; Lee H; Jung J; Kang CK; Song KH; Choe PG; Kim HB; Kim ES; Kim NJ; Seong MW; Park WB; Oh MD; Kwon S; Chung J
    Sci Transl Med; 2021 Jan; 13(578):. PubMed ID: 33397677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes.
    Voss WN; Hou YJ; Johnson NV; Delidakis G; Kim JE; Javanmardi K; Horton AP; Bartzoka F; Paresi CJ; Tanno Y; Chou CW; Abbasi SA; Pickens W; George K; Boutz DR; Towers DM; McDaniel JR; Billick D; Goike J; Rowe L; Batra D; Pohl J; Lee J; Gangappa S; Sambhara S; Gadush M; Wang N; Person MD; Iverson BL; Gollihar JD; Dye JM; Herbert AS; Finkelstein IJ; Baric RS; McLellan JS; Georgiou G; Lavinder JJ; Ippolito GC
    Science; 2021 Jun; 372(6546):1108-1112. PubMed ID: 33947773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses.
    Banach BB; Cerutti G; Fahad AS; Shen CH; Oliveira De Souza M; Katsamba PS; Tsybovsky Y; Wang P; Nair MS; Huang Y; Francino-Urdániz IM; Steiner PJ; Gutiérrez-González M; Liu L; López Acevedo SN; Nazzari AF; Wolfe JR; Luo Y; Olia AS; Teng IT; Yu J; Zhou T; Reddem ER; Bimela J; Pan X; Madan B; Laflin AD; Nimrania R; Yuen KY; Whitehead TA; Ho DD; Kwong PD; Shapiro L; DeKosky BJ
    Cell Rep; 2021 Oct; 37(1):109771. PubMed ID: 34587480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.
    Peterhoff D; Glück V; Vogel M; Schuster P; Schütz A; Neubert P; Albert V; Frisch S; Kiessling M; Pervan P; Werner M; Ritter N; Babl L; Deichner M; Hanses F; Lubnow M; Müller T; Lunz D; Hitzenbichler F; Audebert F; Hähnel V; Offner R; Müller M; Schmid S; Burkhardt R; Glück T; Koller M; Niller HH; Graf B; Salzberger B; Wenzel JJ; Jantsch J; Gessner A; Schmidt B; Wagner R
    Infection; 2021 Feb; 49(1):75-82. PubMed ID: 32827125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain.
    Wu NC; Yuan M; Liu H; Lee CD; Zhu X; Bangaru S; Torres JL; Caniels TG; Brouwer PJM; van Gils MJ; Sanders RW; Ward AB; Wilson IA
    Cell Rep; 2020 Oct; 33(3):108274. PubMed ID: 33027617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of antibody immunity to SARS-CoV-2.
    Gaebler C; Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Tokuyama M; Cho A; Jankovic M; Schaefer-Babajew D; Oliveira TY; Cipolla M; Viant C; Barnes CO; Bram Y; Breton G; Hägglöf T; Mendoza P; Hurley A; Turroja M; Gordon K; Millard KG; Ramos V; Schmidt F; Weisblum Y; Jha D; Tankelevich M; Martinez-Delgado G; Yee J; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Robbiani DF; Zhao Z; Gazumyan A; Schwartz RE; Hatziioannou T; Bjorkman PJ; Mehandru S; Bieniasz PD; Caskey M; Nussenzweig MC
    Nature; 2021 Mar; 591(7851):639-644. PubMed ID: 33461210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.
    Lim SA; Gramespacher JA; Pance K; Rettko NJ; Solomon P; Jin J; Lui I; Elledge SK; Liu J; Bracken CJ; Simmons G; Zhou XX; Leung KK; Wells JA
    MAbs; 2021; 13(1):1893426. PubMed ID: 33666135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
    Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
    Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.
    Dong J; Zost SJ; Greaney AJ; Starr TN; Dingens AS; Chen EC; Chen RE; Case JB; Sutton RE; Gilchuk P; Rodriguez J; Armstrong E; Gainza C; Nargi RS; Binshtein E; Xie X; Zhang X; Shi PY; Logue J; Weston S; McGrath ME; Frieman MB; Brady T; Tuffy KM; Bright H; Loo YM; McTamney PM; Esser MT; Carnahan RH; Diamond MS; Bloom JD; Crowe JE
    Nat Microbiol; 2021 Oct; 6(10):1233-1244. PubMed ID: 34548634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain.
    Tan TJC; Yuan M; Kuzelka K; Padron GC; Beal JR; Chen X; Wang Y; Rivera-Cardona J; Zhu X; Stadtmueller BM; Brooke CB; Wilson IA; Wu NC
    Nat Commun; 2021 Jun; 12(1):3815. PubMed ID: 34155209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity.
    de Mattos Barbosa MG; Liu H; Huynh D; Shelley G; Keller ET; Emmer BT; Sherman E; Ginsburg D; Kennedy AA; Tai AW; Wobus C; Mirabeli C; Lanigan TM; Samaniego M; Meng W; Rosenfeld AM; Prak ETL; Platt JL; Cascalho M
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33769311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
    Wang Z; Muecksch F; Schaefer-Babajew D; Finkin S; Viant C; Gaebler C; Hoffmann HH; Barnes CO; Cipolla M; Ramos V; Oliveira TY; Cho A; Schmidt F; Da Silva J; Bednarski E; Aguado L; Yee J; Daga M; Turroja M; Millard KG; Jankovic M; Gazumyan A; Zhao Z; Rice CM; Bieniasz PD; Caskey M; Hatziioannou T; Nussenzweig MC
    Nature; 2021 Jul; 595(7867):426-431. PubMed ID: 34126625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand.
    Tandhavanant S; Koosakunirand S; Kaewarpai T; Piyaphanee W; Leaungwutiwong P; Luvira V; Chantratita N
    PLoS One; 2021; 16(8):e0255796. PubMed ID: 34375345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
    Bertoglio F; Meier D; Langreder N; Steinke S; Rand U; Simonelli L; Heine PA; Ballmann R; Schneider KT; Roth KDR; Ruschig M; Riese P; Eschke K; Kim Y; Schäckermann D; Pedotti M; Kuhn P; Zock-Emmenthal S; Wöhrle J; Kilb N; Herz T; Becker M; Grasshoff M; Wenzel EV; Russo G; Kröger A; Brunotte L; Ludwig S; Fühner V; Krämer SD; Dübel S; Varani L; Roth G; Čičin-Šain L; Schubert M; Hust M
    Nat Commun; 2021 Mar; 12(1):1577. PubMed ID: 33707427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals.
    Klingler J; Lambert GS; Itri V; Liu S; Bandres JC; Enyindah-Asonye G; Liu X; Simon V; Gleason CR; Kleiner G; Chiu HP; Hung CT; Kowdle S; Amanat F; Lee B; Zolla-Pazner S; Upadhyay C; Hioe CE
    Front Immunol; 2021; 12():759688. PubMed ID: 34987505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.